Preclinical development and first-in-human study of ATX-MS-1467 for immunotherapy of MS

Neurology: Neuroimmunology and NeuroInflammation

Volumn 2, Issue 3, 2015, Pages e93-

  Streeter, Heather B ^a,b   Rigden, Rachel ^a   Martin, Keith F ^a   Scolding, Neil J ^b,c   Wraith, David C ^a,b  

^a Apitope Technology Bristol Ltd   (United Kingdom)

^b UNIVERSITY OF BRISTOL   (United Kingdom)

^c SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLATIRAMER; HLA ANTIGEN CLASS 2; IMMUNOLOGIC AGENT; INTERLEUKIN 10; RNA;

AMINO ACID SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC THERAPY; CLINICAL ASSESSMENT; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FIRST IN HUMAN STUDY; HAPLOTYPE; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL MONITORING; IMMUNOTHERAPY; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRECLINICAL STUDY; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TRANSGENIC MOUSE; URINARY TRACT INFECTION; VISUAL ACUITY;

EID: 84953229687     PISSN: None     EISSN: 23327812     Source Type: Journal    
DOI: 10.1212/NXI.0000000000000093     Document Type: Review

References (38)

1. Giacomini PS, Darlington PJ, Bar-Or A. Emerging multiple sclerosis disease-modifying therapies. Curr Opin Neurol 2009;22:226-232.
2. Garber K. Immunology: a tolerant approach. Nature 2014;507:418-420.
3. Larche M, Wraith DC. Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat Med 2005;11: S69-S76.
4. Anderton SM, Viner NJ, Matharu P, Lowrey PA, Wraith DC. Influence of a dominant cryptic epitope on autoimmune T cell tolerance. Nat Immunol 2002;3:175-181.
5. Santambrogio L, Sato AK, Fischer FR, Dorf ME, Stern LJ. Abundant empty class II MHC molecules on the surface of immature dendritic cells. Proc Natl Acad Sci USA 1999; 96:15050-15055.
6. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003;21:685-711.
7. Metzler B, Wraith DC. Inhibition of T-cell responsiveness by nasal peptide administration: influence of the thymus and differential recovery of T-cell-dependent functions. Immunology 1999;97:257-263.
8. Burkhart C, Liu GY, Anderton SM, Metzler B, Wraith DC. Peptide-induced T cell regulation of experimental autoimmune encephalomyelitis: a role for IL-10. Int Immunol 1999;11:1625-1634.
9. Gabrysova L, Nicolson KS, Streeter HB, et al. Negative feedback control of the autoimmune response through antigen-induced differentiation of IL-10-secreting Th1 cells. J Exp Med 2009;206:1755-1767.
10. Metzler B, Wraith DC. Inhibition of experimental autoimmune encephalomyelitis by inhalation but not oral administration of the encephalitogenic peptide: influence of MHC binding affinity. Int Immunol 1993;5:1159-1165.
11. Anderton SM, Wraith DC. Hierarchy in the ability of T cell epitopes to induce peripheral tolerance to antigens from myelin. Eur J Immunol 1998;28:1251-1261.
12. Liu JQ, Bai XF, Shi FD, et al. Inhibition of experimental autoimmune encephalomyelitis in Lewis rats by nasal administration of encephalitogenic MBP peptides: syner-gistic effects of MBP 68-86 and 87-99. Int Immunol 1998;10:1139-1148.
13. Walczak A, Siger M, Ciach A, Szczepanik M, Selmaj K. Transdermal application of myelin peptides in multiple sclerosis treatment. JAMA Neurol 2013;70:1105-1109.
14. Mazza G, Ponsford M, Lowrey P, Campbell MJ, Zajicek J, Wraith DC. Diversity and dynamics of the T-cell response to MBP in DR21ve individuals. Clin Exp Immunol 2002;128:538-547.
15. Fairchild PJ, Wildgoose R, Atherton E, Webb S, Wraith DC. An autoantigenic T cell epitope forms unstable complexes with class II MHC: a novel route for escape from tolerance induction. Int Immunol 1993;5:1151-1158.
16. Madsen LS, Andersson EC, Jansson L, et al. A humanized model for multiple sclerosis using HLA-DR2 and a human T-cell receptor. Nat Genet 1999;23:343-347.
17. McDonald WI, Compston A, Edan G, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121-127.
18. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-1452.
19. Plebanski M, Burtles SS. In vitro primary responses of human T cells to soluble protein antigens. J Imm Meth 1994;170:15-25.
20. Ponsford M, Mazza G, Coad J, Campbell MJ, Zajicek J, Wraith DC. Differential responses of CD451ve T-cell subsets to MBP in multiple sclerosis. Clin Exp Immunol 2001;124:315-322.
21. Stordeur P, Poulin LF, Craciun L, et al. Cytokine mRNA quantification by real-time PCR. J Immunol Methods 2002;259:55-64.
22. Wucherpfennig KW, Zhang J, Witek C, et al. Clonal expansion and persistence of human T cells specific for an immunodominant myelin basic protein peptide. J Immunol 1994;152:5581-5592.
23. Sundstedt A, O'Neill EJ, Nicolson KS, Wraith DC. Role for IL-10 in suppression mediated by peptide-induced regulatory T cells in vivo. J Immunol 2003;170:1240-1248.
24. Kappos L, Comi G, Panitch H, et al. Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. Nat Med 2000;6:1176-1182.
25. Pedotti R, Mitchell D, Wedemeyer J, et al. An unexpected version of horror autotoxicus: anaphylactic shock to a self-peptide. Nat Immunol 2001;2:216-222.
26. Smith CE, Eagar TN, Strominger JL, Miller SD. Differential induction of IgE-mediated anaphylaxis after soluble vs. cell-bound tolerogenic peptide therapy of autoimmune encephalomyelitis. Proc Natl Acad Sci USA 2005;102: 9595-9600.
27. Johnson KP, Brooks BR, Ford CC, et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Mult Scler 2000;6:255-266.
28. Teitelbaum D, Fridkis-Hareli M, Arnon R, Sela M. Copolymer 1 inhibits chronic relapsing experimental allergic encephalomyelitis induced by proteolipid protein (PLP) peptides in mice and interferes with PLP-specific T cell responses. J Neuroimmunol 1996;64:209-217.
29. Stern JN, Keskin DB, Zhang H, Lv H, Kato Z, Strominger JL. Amino acid copolymer-specific IL-10-secreting regulatory T cells that ameliorate autoimmune diseases in mice. Proc Natl Acad Sci USA 2008;105: 5172-5176.
30. Oldfield WL, Larche M, Kay AB. Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised con-trolled trial. Lancet 2002;360:47-53.
31. Müller U, Akdis CA, Fricker M, et al. Successful immu-notherapy with T-cell epitope peptides of bee venom phos-pholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 1998; 101:747-754.
32. Liu GY, Fairchild PJ, Smith RM, Prowle JR, Kioussis D, Wraith DC. Low avidity recognition of self-antigen by T cells permits escape from central tolerance. Immunity 1995;3:407-415.
33. Harrington CJ, Paez A, Hunkapiller T, et al. Differential tolerance is induced in T cells recognizing distinct epitopes of myelin basic protein. Immunity 1998;8:571-580.
34. Targoni OS, Lehmann PV. Endogenous myelin basic protein inactivates the high avidity T cell repertoire. J Exp Med 1998;187:2055-2063.
35. Manoury B, Mazzeo D, Fugger L, et al. Destructive processing by asparagine endopeptidase limits presentation of a dominant T cell epitope in MBP. Nat Immunol 2002;3: 169-174.
36. Shen CR, Youssef AR, Devine A, et al. Peptides containing a dominant T-cell epitope from red cell band 3 have in vivo immunomodulatory properties in NZB mice with autoimmune hemolytic anemia. Blood 2003;102: 3800-3806.
37. Bielekova B, Goodwin B, Richert N, et al. Encephalito-genic potential of the myelin basic protein peptide (aminoacids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 2000;6:1167-1175.
38. Burton BR, Britton GJ, Fang H, et al. Sequential tran-scriptional changes dictate safe and effective antigen-specific immunotherapy. Nat Commun 2014;5:4741.